ticagrelor and Ovarian-Neoplasms

ticagrelor has been researched along with Ovarian-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for ticagrelor and Ovarian-Neoplasms

Article	Year
Role of ADP receptors on platelets in the growth of ovarian cancer. Blood, 2017, 09-07, Volume: 130, Issue:10 We investigated the effect of platelets on ovarian cancer and the role of adenosine diphosphate (ADP) receptors (P2Y12 and P2Y1) on platelets in the growth of primary ovarian cancer tumors. We showed that in murine models of ovarian cancer, a P2Y12 inhibitor (ticagrelor) reduced tumor growth by 60% compared with aspirin and by 75% compared with placebo. In P2Y12 Topics: Adenosine; Adoptive Transfer; Animals; Antigens, CD; Apoptosis; Apyrase; Blood Platelets; Cell Proliferation; Female; Gene Knockdown Techniques; Hematopoiesis; Humans; Mice, Inbred C57BL; Ovarian Neoplasms; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor	2017

Article

Year

Role of ADP receptors on platelets in the growth of ovarian cancer.

Blood, 2017, 09-07, Volume: 130, Issue:10

We investigated the effect of platelets on ovarian cancer and the role of adenosine diphosphate (ADP) receptors (P2Y12 and P2Y1) on platelets in the growth of primary ovarian cancer tumors. We showed that in murine models of ovarian cancer, a P2Y12 inhibitor (ticagrelor) reduced tumor growth by 60% compared with aspirin and by 75% compared with placebo. In P2Y12

Topics: Adenosine; Adoptive Transfer; Animals; Antigens, CD; Apoptosis; Apyrase; Blood Platelets; Cell Proliferation; Female; Gene Knockdown Techniques; Hematopoiesis; Humans; Mice, Inbred C57BL; Ovarian Neoplasms; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor

2017